SOUTH SAN FRANCISCO, Calif. , Dec. 04, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics , Inc. (GBT) (NASDAQ: GBT) today announced that on December 1, 2019 , the compensation committee of GBT’s board of directors granted 21 new employees options to purchase an aggregate of 13,000 shares of the

SOUTH SAN FRANCISCO, Calif. , Nov. 26, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the following investor conferences in December 2019 : Evercore ISI 2 nd Annual HealthCONx Conference in Boston on Tuesday, December 3, 2019 at

First and only FDA -approved sickle hemoglobin polymerization inhibitor, a new class of therapy Oxbryta broadly indicated for the treatment of sickle cell disease in adults and children 12 years of age and older 1 Approval comes three months ahead of FDA’s priority review action date, allowing for

SOUTH SAN FRANCISCO, Calif. , Nov. 07, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported recent business progress and financial results for the third quarter ended September 30, 2019 . “With the recent FDA acceptance of our NDA filing for voxelotor, we are

Abstracts Include Three Post -hoc Analyses of Phase 3 HOPE Study Clinical Data Data Further Support the Safety and Efficacy of Voxelotor for Sickle Cell Disease (SCD) Examination of Real-world Evidence Further Establishes Relationship Between Higher Levels of Hemoglobin and Decreased Risk of Stroke

SOUTH SAN FRANCISCO, Calif. , Nov. 04, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. , (GBT) (NASDAQ: GBT) today announced that on November 1, 2019 , the compensation committee of GBT’s board of directors granted 72 new employees options to purchase an aggregate of 55,100 shares of the

First of Several Post -hoc Analyses Planned Using HOPE Study Clinical Data Findings Presented in Poster Session at 13 th Annual Academy for Sickle Cell and Thalassemia Conference SOUTH SAN FRANCISCO, Calif. , Oct. 21, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc.

SOUTH SAN FRANCISCO, Calif. , Oct. 07, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. , (GBT) (NASDAQ: GBT) today announced that on October 1, 2019 , the compensation committee of GBT’s board of directors granted 12 new employees options to purchase an aggregate of 24,600 shares of the

SOUTH SAN FRANCISCO, Calif. , Oct. 02, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that four abstracts related to its sickle cell disease (SCD) research have been accepted for oral and poster presentations during the 47 th Annual National Sickle Cell

SOUTH SAN FRANCISCO, Calif. , Oct. 01, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. , (GBT) (NASDAQ: GBT) today announced that it will host an Analyst & Investor Day to provide an update to the investment community on the company’s development and commercial strategy for voxelotor for

SOUTH SAN FRANCISCO, Calif. , Sept. 25, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 2019 Cantor Global Healthcare Conference in New York City on Wednesday, October 2, 2019 , at 10:05 a.m. Eastern Time .

Priority Review Shortens FDA Review Time to Six Months from Standard 10 Months NDA Supported by Data from Phase 3 HOPE Study, which Demonstrated Statistically Significant and Sustained Improvements in Hemoglobin with Voxelotor SOUTH SAN FRANCISCO, Calif. , Sept.

SOUTH SAN FRANCISCO, Calif. , Sept. 04, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics , Inc. (GBT) (NASDAQ: GBT) today announced that on September 1, 2019 , the compensation committee of GBT’s board of directors granted Eric Fink and 8 new employees options to purchase an aggregate of 47,600

SOUTH SAN FRANCISCO, Calif. , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 2019 Morgan Stanley Global Healthcare Conference in New York City on Monday, September 9, 2019 , at 2:50 p.m. Eastern Time .

Patient Advocates, Healthcare Providers and Policy Makers to Discuss the Latest Advances and Future Trends for Treating Patients with SCD Conference Taking Place During National Sickle Cell Awareness Month Livestream of Conference will be Available through Collaboration with Sickle Cell Warriors

SOUTH SAN FRANCISCO, Calif. , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported recent business progress and financial results for the second quarter ended June 30, 2019 . “We accomplished several significant milestones in the second quarter of

SOUTH SAN FRANCISCO, Calif. , Aug. 06, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 2019 Wedbush PacGrow Healthcare Conference in New York City on Tuesday, August 13, 2019 , at 1:55 p.m. Eastern Time .

SOUTH SAN FRANCISCO, Calif. , Aug. 02, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics , Inc. (GBT) (NASDAQ: GBT) today announced that on August 1, 2019 , the compensation committee of GBT’s board of directors granted 14 new employees options to purchase an aggregate of 26,200 shares of the

Company Also Launches Disease Awareness Campaign to Raise Awareness Among Physicians About the Silent Damage Caused by Sickle Cell Disease SOUTH SAN FRANCISCO, Calif. , July 10, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), in partnership with sickle cell

SOUTH SAN FRANCISCO, Calif. , July 09, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics , Inc. (GBT) (NASDAQ: GBT) today announced that on July 1, 2019 , the compensation committee of GBT’s board of directors granted 13 new employees options to purchase an aggregate of 4,000 shares of the

SOUTH SAN FRANCISCO, Calif. , June 26, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics , Inc. (GBT) (Nasdaq: GBT), a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities, today announced

SOUTH SAN FRANCISCO, Calif. , June 25, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (Nasdaq: GBT), a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities, today announced an

Data Supporting the Potential of Voxelotor as a Disease-Modifying Treatment for Sickle Cell Disease (SCD) Published in The New England Journal of Medicine and to be Presented During Presidential Symposium at the 24 th European Hematology Association (EHA) Congress Additional Clinical Data

Company Created ACCEL (Access to Excellent Care for Sickle Cell Patients Pilot Program) to Accelerate Development of Innovative Healthcare Programs for Sickle Cell Community SOUTH SAN FRANCISCO, Calif. , June 10, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc.

SOUTH SAN FRANCISCO, Calif. , June 07, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics , Inc. (GBT) (NASDAQ: GBT) today announced that on June 1, 2019 , the compensation committee of GBT’s board of directors granted 19 new employees options to purchase an aggregate of 35,600 shares of the

Phase 3 HOPE Study 24-Week Efficacy Results from Full Patient Cohort  to be Presented During Presidential Symposium New Drug Application (NDA) Submission Planned for Voxelotor to Include HOPE Study Data Being Presented at EHA 2019 Company to Host Investor Webcast on Friday, June 14 SOUTH SAN

SOUTH SAN FRANCISCO, Calif. , May 08, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics , Inc. (GBT) (NASDAQ: GBT) today reported recent business progress and financial results for the first quarter ended March 31, 2019. “With a goal of getting voxelotor to the sickle cell community as quickly as

SOUTH SAN FRANCISCO, Calif. , May 06, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics , Inc. (GBT) (NASDAQ: GBT) today announced that on May 1, 2019 , the compensation committee of GBT’s board of directors granted nine new employees options to purchase an aggregate of 24,600 shares of the

SOUTH SAN FRANCISCO, Calif. , April 03, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics , Inc. (GBT) (NASDAQ: GBT) today announced that on April 1, 2019 , the compensation committee of GBT’s board of directors granted 10 new employees restricted stock units representing an aggregate of 30,500

SOUTH SAN FRANCISCO, Calif. , April 02, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the H.C. Wainwright Global Life Sciences Conference in London on Tuesday, April 9, 2019 , at 10:10 a.m. British Summer Time.

SOUTH SAN FRANCISCO, Calif. , March 06, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics , Inc. (GBT) (NASDAQ: GBT) today announced that on March 1, 2019 , the compensation committee of GBT’s board of directors granted 10 new employees options to purchase an aggregate of 76,100 shares of the

SOUTH SAN FRANCISCO, Calif. , March 04, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the Cowen and Company 39 th Annual Health Care Conference in Boston on Monday, March 11, 2019 , at 4:50 p.m. Eastern Time .

Pre-NDA Meeting Completed and Company Announces FDA Agreed to a Rolling Submission of New Drug Application for Voxelotor for the Potential Treatment of Sickle Cell Disease SOUTH SAN FRANCISCO, Calif. , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics , Inc. (GBT) (NASDAQ: GBT) today

SOUTH SAN FRANCISCO, Calif. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York on Thursday, February 28, 2019 , at 1 p.m. Eastern Time .

—The Access to Excellent Care for Sickle Cell Patients Pilot Program ( ACCEL ) Supports Novel Projects Aimed at Improving Access to High-Quality Healthcare for People with Sickle Cell Disease— —GBT Will Fund Proposals With the Highest Potential to Impact Patient Care— SOUTH SAN FRANCISCO, Calif.